Hodgkin’s Lymphoma – Opportunity Analysis and Forecasts to 2029

Price :
Published : Jun-2020
No. of Pages : 140

Hodgkin’s Lymphoma – Opportunity Analysis and Forecasts to 2029


HL is a rare hematological malignancy that arises from the lymphatic system. Although HL is a rare condition, it has a high cure rate due to the positive response to treatment which combines chemotherapy, targeted therapy, radiotherapy and stem cell transplant accordingly. The World Health Organization (WHO) classifies HL into two main types: classical HL (CHL) and nodular lymphocyte-predominant HL (NLPHL), which CHL accounts for 95% of cases. Historically, treatment of HL has been mostly reliant on chemotherapies, radiotherapy and SCT and has lacked a rapidly advancing pipeline.

In recent years however, the arrival of three novel agents reflect a change in the treatment paradigm, shifting from cytotoxic therapies to immunotherapies and novel cell-based therapies. GlobalData is expecting a total of 6 new entrants to launch over the forecast period in the 8MM from 2019-2029, while specific marketed agents are expected to move into earlier lines of treatment as novel combinations. The main competition will between drug entering the first-line setting and novel combinations within the salvage setting for relapsed and refractory patients. Given the high cure rate for this indication, these two early setting are the most determinant of global sales for Hodgkin’s lymphoma.

Key Highlights

– The main drivers of growth include the anticipated label expansions of currently marketed therapies across the 8MM during the forecast period.
– The main barriers to growth in the 8MM include the patent expiry of the market leading drugs and the lack of premium priced therapeutics entering the market.
– Among the late-stage pipeline products and marketed agents, marketed drug combinations and CAR-T cell therapies are expected to generate the greatest revenues over the forecast period.
– The most important unmet needs in the Hodgkin’s lymphoma market include: improving cure rates in the first-line treatment setting, more options available for relapsed and refractory patients and alternative treatments to stem cell transplants.


– Six late-stage pipeline agents are going to enter Hodgkin lymphoma market from 2019 onwards. What the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
– What are the current unmet needs in Hodgkin’s lymphoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
– What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
– What are the main corporate trends? Who are the current and future players?


– Overview of Hodgkin’s lymphoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Topline Hodgkin’s lymphoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
– Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Hodgkin’s lymphoma therapeutics sales in the 8MM.
– Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
– Analysis of the current and future market competition in the global Hodgkin’s lymphoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
– Develop business strategies by understanding the trends shaping and driving the global Hodgkin’s lymphoma therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Hodgkin’s lymphoma market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global Hodgkin’s lymphoma therapeutics market from 2019-2029.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Teleradiology Market by Products & Services (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers & Laboratories), COVID-1 Impact – Forecast to 2025

“Dearth of skilled radiologists & need for faster and improved diagnosis are driving market growth” The teleradiology market is expected to reach USD 22.8 billion by 2025 from USD 7.9 billion in 2020, at a CAGR of 23.5% during the forecast period of 2020 to 2025. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for teleradiology services. The growth of this market is mainly attributed to the rising geriatric population and the subsequent increase in the prevalence of associated diseases, the increasing adoption of cloud-based solutions, and the benefits offered by teleradiology and a dearth of skilled radiologists. However, declining reimbursements and increasing regulatory burden in the US and data breaching of imaging report hampered market gr......

Coronavirus Disease 2019 – Epidemiology Analysis and Forecast – June 2020

Coronavirus Disease 2019 - Epidemiology Analysis and Forecast - June 2020 Summary The pandemic's epicenters have shifted to Latin America, India, Pakistan, and South Africa. COVID-19 is mainly affecting the dense populous and poorer regions of these countries. As a result, the global daily confirmed cases are increasing at a higher pace than before. The US continues to be the most affected country globally, reaching close to 2.5 million cases. The US reported the highest number of new daily cases on 26 June since the start of the pandemic. Chile moves up ahead of Spain. Brazil has now reported more than 1 million total confirmed cases of COVID-19. Mexico is now ranked 11th among the top most affected countries. The report covers current epidemiology situation, forecast, and analysis ......

Amyloidosis – Epidemiology Forecast to 2029

Amyloidosis - Epidemiology Forecast to 2029 Summary Amyloidosis is a rare disease characterized by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alters the normal functions of the tissues in the organs (Holmes et al., 2019; Mayo Clinic, 2020). Amyloid is not normally found in the body, but it can be formed from several different types of protein and interferes with the organs' normal function. Organs that may be affected by amyloidosis include the heart, kidneys, liver, spleen, nervous system, and digestive tract (Mayo Clinic, 2020). The signs and symptoms of amyloidosis include dizziness, fluid retention, fatigue, fainting, an enlarged tongue, low blood pressure, and shortness of breath (Mayo Clinic, 2020; Stanford Health Care, 2020). There ar......

Transthyretin Amyloidosis – Global Drug Forecast and Market Analysis to 2029

Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029 Summary Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis diagnoses are made later in life, with the average patient aged 65 at diagnosis. Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein an......

Impact on Publicly Traded Bio/Pharma Companies – Coronavirus Disease (COVID-19) 2019 Impact Report

Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Scope - This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.......

Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029 Summary Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019 to $5.1B in 2029 at a compound annual growth rate (CAGR) of 13.6%. This dramatic growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the......

Acute Myeloid Leukemia – Epidemiology Forecast to 2029

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Gr......

Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) – Global Forecast to 2025

 “The aseptic sampling market is projected to grow at a CAGR of 12.4% during the forecast period (2020–2025).” The global aseptic sampling market size is projected to reach USD 474 million by 2025 from USD 264 million in 2020, at a CAGR of 12.4%. The growth of this market is driven majorly by factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities. On the other hand, issues related to leachables and extractable from single-use products are restraining market growth. “By type, the manual aseptic sampling segment is expected to grow at the highest CAGR during the forecast period.” Based on type, the aseptic sampling market is segmented into manual aseptic......

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. Scope The report includes 10 Influencers - - Eight therapy areas: Cardiovascular, Metabolic Disord......

Digital Biomarkers – Coronavirus Disease 2019 (COVID-19) Case Study

Digital Biomarkers - Coronavirus Disease 2019 (COVID-19) Case Study Summary The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond. Key Highlights - Digital biomarkers are an important addition to the armamentarium of tools supporting pa......
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy